Media Articles Related to Cardene SR (Nicardipine)
Renal Denervation for Uncontrolled Hypertension
Source: Medscape Critical Care Headlines [2017.03.20]
Is renal denervation an effective option for managing uncontrolled hypertension?
Current Opinion in Nephrology and Hypertension
New role for immune cells in preventing diabetes and hypertension
Source: Diabetes News From Medical News Today [2017.03.20]
Immune cells which are reduced in number by obesity could be a new target to treat diseases such as type 2 diabetes and hypertension that affect overweight people, according to a collaborative...
Study reveals link between hypertension and brain changes in rats
Source: Hypertension News From Medical News Today [2017.03.10]
New research investigates the changes in brain activity and arterial blood flow that occur with the onset of hypertension in rats.
Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
Source: Hypertension News From Medical News Today [2017.02.28]
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published in Pediatrics demonstrates...
Late-onset hypertension may lower dementia risk, study finds
Source: Hypertension News From Medical News Today [2017.01.17]
For the first time, a study investigates the link between high blood pressure later in life and the risk of dementia and cognitive decline.
Published Studies Related to Cardene SR (Nicardipine)
Development of nicardipine prolonged-release implants after clipping for
preventing cerebral vasospasm: from laboratory to clinical trial. 
We have developed a drug delivery system using a vasodilating drug that can be
implanted intracranially at the time of surgery for aneurysm clipping, without
systemic side effects or side effects associated with long-term intrathecal drug
administration.We have performed three studies (a
single-center study with consecutive patients; a single-center, randomized,
double-blind trial; and a multicenter cooperative study) and have proved that
implantation of NPRIs reduces the incidence of cerebral vasospasm and DINDs and
improves clinical outcome after SAH.
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. 
INTRODUCTION: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension... CONCLUSIONS: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.
Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]
INTRODUCTION: Various conservative treatments for Peyronie's disease (PD) have been attempted over the years. Intralesional verapamil injection has been tested in prospective randomized studies, but the effect of this treatment seems insufficient. Nicardipine is a calcium antagonist alternative to verapamil and is reportedly more effective in vitro. AIM: The objective of our study was to evaluate the usefulness of intralesional nicardipine injection as a conservative treatment for PD in the transition period of acute and chronic phase... CONCLUSION: Our findings indicate that intralesional nicardipine injection is clinically effective as a conservative treatment for PD in the transition period of acute and chronic phase. (c) 2010 International Society for Sexual Medicine.
Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. [2009.06]
BACKGROUND: Elevation in cardiac enzymes after percutaneous coronary intervention (PCI) is common and is associated with adverse clinical outcomes. HYPOTHESIS: Administration of intracoronary nicardipine-a calcium channel blocker will reduce cardiac enzyme levels in patients undergoing elective PCI... CONCLUSIONS: In low-risk patients undergoing elective PCI, intracoronary nicardipine administration did not produce a significant cardioprotective effect in reducing postprocedural cardiac enzymes leakage. Copyright (c) 2009 Wiley Periodicals, Inc.
Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. [2009.05]
OBJECTIVES: To investigate the renoprotective effect of nicardipine in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP) in a prospective trial. Superior visualization of the increasingly performed RALRP requires pneumoperitoneum and extreme head-down tilt, both of which are associated with a decrease in postoperative renal function. Nicardipine causes preferential dilation of the renal arterioles and attenuates renal dysfunction after cardiac surgery... CONCLUSIONS: Continuous infusion of low-dose nicardipine during RALRP seems to offset the deleterious effects of inevitable pneumoperitoneum and extreme head-down tilt on renal function in preserving the eGFR and attenuating the development of renal insufficiency in the immediate postoperative period.
Clinical Trials Related to Cardene SR (Nicardipine)
A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension [Withdrawn]
To define the relationship between Cardene I. V. dose, serum concentrations, and blood
pressure reduction in pediatric subjects with hypertension.
Safety Study of Nicardipine to Treat Cerebral Vasospasm [Terminated]
Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Completed]
Effect of Nicardipine on Renal Function in Deliberate Hypotension [Completed]
The aim of this study was to demonstrate the effect of nicardipine on renal function with
creatinine clearance, serum cystatin C, urine output and fractional excretion of sodium
during deliberate hypotension for spine surgery.
IV Double and Triple Concentrated Nicardipine for Stroke and ICH [Recruiting]
Hypertension (high blood pressure) can often cause neurological worsening in patients with
stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of
nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of
Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The
purpose of this study is to evaluate safety and efficacy of double or triple concentrated
peripheral intravenous (IV) Nicardipine.